Other languages Compugen Ltd.

Equities

CGEN

IL0010852080

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
2.16 ^USD	+8.54%		+13.09%	+9.09%

08/03	Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating	MT
05/03	Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Compugen Ltd. Announces Executive Changes	15/02
Sector Update: Health Care Stocks Stronger Late Afternoon	20/12
Sector Update: Health Care	20/12
Looming Inflation Data Stifle US Equity Futures Pre-Bell	19/12
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar	19/12
Top Midday Gainers	20/12
Top Premarket Gainers	19/12
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	19/12
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	19/12
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule	04/11
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer	31/23/31
Sector Update: Health Care Stocks Retreating Monday Afternoon	02/23/02
Compugen Gets Japanese Patent for Cancer Combination Therapy	02/23/02
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	02/23/02
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/23/07
Compugen Says European Patent Office Rules in Favor of Maintaining Claims to Patent on Cancer Treatment	17/23/17
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party	17/23/17
Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study	22/23/22
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Compugen Ltd.

Equities

CGEN

IL0010852080

Other languages

Filters